Precigen (PGEN) Total Non-Current Liabilities (2012 - 2026)
Precigen (PGEN) posted quarterly Total Non-Current Liabilities of $118.3 million for Q1 2026, up 290.24% year-over-year from $30.3 million in Q1 2025, and down 12.03% quarter-over-quarter from $134.5 million in Q4 2025.
Precigen (PGEN) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Total Non-Current Liabilities for 15 consecutive years, with $118.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 290.24% year-over-year to $118.3 million; the TTM figure through Mar 2026 stood at $118.3 million (up 290.24% YoY), while the FY2025 annual figure was $134.5 million, up 71.21% from the prior year.
- Total Non-Current Liabilities fell to $118.3 million in Q1 2026 per PGEN's latest filing, from $134.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $261.7 million in Q1 2022 and bottomed at $29.2 million in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $101.8 million across 5 years, with a median of $98.4 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities increased 12.75% — and 2026, when it surged 290.24%.
- Precigen's Total Non-Current Liabilities stood at $261.7 million in 2022, then slumped by 87.56% to $32.5 million in 2023, then jumped by 141.31% to $78.5 million in 2024, then soared by 71.21% to $134.5 million in 2025, then dropped by 12.03% to $118.3 million in 2026.
- Business Quant data shows PGEN's Total Non-Current Liabilities at $118.3 million in Q1 2026, $134.5 million in Q4 2025, and $129.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 126.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 126.64 Mn |
| Mar 31, 2026 | 118.29 Mn |
| Dec 31, 2025 | 134.46 Mn |
| Sep 30, 2025 | 129.40 Mn |
| Jun 30, 2025 | 29.23 Mn |
| Mar 31, 2025 | 30.31 Mn |
| Dec 31, 2024 | 78.54 Mn |
| Dec 31, 2023 | 32.55 Mn |
| Mar 31, 2022 | 261.68 Mn |
| Dec 31, 2021 | 252.46 Mn |
| Sep 30, 2021 | 245.60 Mn |
| Jun 30, 2021 | 243.33 Mn |
| Mar 31, 2021 | 232.09 Mn |
| Dec 31, 2020 | 247.31 Mn |
| Sep 30, 2020 | 277.53 Mn |
| Jun 30, 2020 | 312.07 Mn |
| Dec 31, 2019 | 88,000.00 |
| Sep 30, 2019 | 376.26 Mn |
| Jun 30, 2019 | 375.74 Mn |
| Mar 31, 2019 | 374.38 Mn |